CMS Launches First Wave HealthTech Ecosystem Tools, 700+ Orgs Pledged
CMS announced the First Wave Launch of its HealthTech Ecosystem, featuring interoperable digital tools for patient data access and streamlined care. Over 700 organizations have pledged support for the initiative, which aims to modernize healthcare delivery by replacing traditional paperwork with digital-first solutions.
Health Canada Consults on Antimicrobial Drug CAN-AWaRe Classification
Health Canada has opened a 60-day public consultation on the proposed Canadian Access, Watch, Reserve (CAN-AWaRe) classification framework for antimicrobial drugs for human use. The consultation runs until June 8, 2026, and seeks feedback from healthcare professionals, industry, academia, and public health agencies on the proposed classification of antibacterial drugs. Comments will inform the finalization of the CAN-AWaRe framework.
OSHA Logging Operations Standard
OSHA has issued a final rule updating the Logging Operations Standard (29 CFR 1910.266), addressing safety requirements for chainsaws, machine guarding, personal protective equipment, and training in logging workplaces. The revised standard affects approximately 1,600 logging establishments with 54,000 workers.
DEX Ophthalmic Forceps Recall Katalyst Surgical Carl Zeiss Meditec
ANSM issued safety alert R2609552 informing French health establishments of a recall by Carl Zeiss Meditec for DEX ophthalmic forceps and scissors manufactured by Katalyst Surgical LLC. Affected health facilities must remove the devices from use and contact the manufacturer directly. The safety action letter was published April 9, 2026.
Recall Mycology Yeastone Broth 11ML Remel - R2609813
ANSM registered safety action R2609813 for Mycology Yeastone Broth 11ML Remel following a lot withdrawal initiated by Thermo Fisher. Medical biology laboratories that received the affected product have been notified directly by Thermo Fisher. This recall addresses a safety concern with specific lots of the reagent used in mycological testing.
Advanced Bionics Cochlear Implant Battery Compartment Recall, 847 Units
ANSM recorded a lot withdrawal by Advanced Bionics LLC for cochlear implant battery compartments (model ZN Air M CI-5501). The action, registered as R2609192, affects 847 units. Health establishments received direct notification from the company with instructions for identifying and returning affected devices.
Elekta Cervical/Intrauterine Brachytherapy System Safety Recall
ANSM published safety alert R2610148 informing healthcare facilities of a medical device safety action by Elekta regarding its cervical/intrauterine brachytherapy system. Users of affected devices have received direct notification from Elekta. The recall is effective April 9, 2026, and healthcare providers using this radiation therapy equipment must take immediate action.
SFDA and Mawani Convene 220+ Industry Representatives on Supply Chain Resilience
The SFDA CEO hosted a virtual meeting with over 220 representatives from food, pharmaceutical, and medical device companies to discuss supply chain resilience. Key initiatives highlighted include the 'Fast Track' partnership with Mawani for expedited port clearance and the SFDA-Saudia Cargo collaboration for pharmaceutical logistics. The SFDA also detailed its 24/7 Response Center and expanded inspection capacity at ports of entry.
FormPour Warning Letter - Unapproved New Drug Sales via eBay
FDA issued a warning letter to FormPour (Shuja Arshad) for selling an unapproved new drug product, the 'SMGT-GLT-1 Nano Microneedle Patch,' on eBay. The product makes unapproved claims for treating Type 2 diabetes, weight loss, and cardiovascular protection, violating sections 301(d) and 505(a) of the FD&C Act. The recipient has 15 working days to respond with corrective actions or face seizure and injunction.
Pure Indulgence Aesthetics - DSCSA Trading Partner and Product Tracing Violations
FDA issued a Warning Letter to Pure Indulgence Aesthetics, a medical spa in Southlake, TX, identifying DSCSA violations under Section 582(d) of the FD&C Act. Investigators found the firm dispensed significantly more Botox units than documented in purchase records from AbbVie, indicating potential sourcing from unauthorized trading partners. The firm must respond with corrective actions within the specified timeframe.
DNV Healthcare Hospital Accreditation Comment
DNV Healthcare submitted a public comment to CMS on proposed hospital accreditation standards (CMS-2026-1288). The comment was filed through Regulations.gov as part of the federal rulemaking consultation process. The specific content of the comment is not visible in this form submission record.
DNV Healthcare Seeks Continued CMS Hospital Accreditation Recognition
CMS published a notice acknowledging receipt of DNV Healthcare USA Inc.'s application for continued recognition as a national accrediting organization for hospital accreditation. The application would allow DNV to continue certifying hospitals for participation in Medicare and Medicaid programs under Section 1865(a)(1)(A) of the Social Security Act. Public comments are being accepted until May 11, 2026.
DEA Baltimore Seizes Over 10,000 Fentanyl-Laced Gel Capsules
DEA Baltimore division and law enforcement partners seized over 10,000 gel capsules containing fentanyl in Baltimore. The counterfeit capsules were packaged to resemble candy or vitamins and were prepared for immediate street distribution. DEA issued a public safety alert warning the public not to be deceived by the deceptive packaging.
CAR TCR Cell Therapy Patent Improves Cytokine Signaling
USPTO published patent application US20260098074A1 by inventors Ruth E. Winter and Saikat Banerjee for CAR and/or TCR cell therapy improving cytokine signaling. The patent covers methods for enhancing immune cell function through improved cytokine signaling pathways in cell therapy applications. The application was filed on 2025-07-15.
Modified LGICs with Altered Ligand Binding, Ion Pore Domains
USPTO published patent application US20260098076A1 for modified ligand-gated ion channels (LGICs) with altered ligand binding domains and ion pore domains. The invention covers exogenous LGIC ligands, methods for modulating ion transport and cell excitability in mammals, and methods for treating channelopathies. The application was filed on February 24, 2025.
METHOD FOR TREATING MEMBRANOUS NEPHROPATHY WITH TACI-FC FUSION PROTEIN
USPTO published patent application US20260098077A1 for a method of treating membranous nephropathy using TACI-Fc fusion protein. The application, filed September 28, 2023, discloses dosage schemes, administration intervals, and clinical efficacy data showing good safety profiles in patients.
Macrocycle and Hydrophobic Particle Method for Removing Polymers from Protein Solutions
USPTO published patent application US20260098055A1 for a method of removing free polymers from solutions containing hydrophobic proteins using macrocycles and/or hydrophobic particles. The application (CPC C07K 1/145) was filed September 7, 2023, with inventors including Barbara Maertens and colleagues. This pre-grant publication does not confer any enforceable rights.
Washington University Patents UTI Treatment Using Hemolysin Inhibitor
The USPTO published Washington University's patent application (US20260098073A1) for compositions and methods treating urinary tract infection and sepsis using alpha-hemolysin (HlyA) inhibiting agents. The technology includes soluble LDLR-Fc fusion proteins, clathrin-mediated endocytosis inhibitors, and anti-LDLR antibodies targeting E. coli hemolysin. This grants Washington University exclusive IP rights over these therapeutic compositions.
Methods for Constructing Conjugates Using Ortho-Phthalaldehyde
USPTO published Patent Application US20260098054A1 disclosing methods for constructing conjugates using ortho-phthalaldehyde. The method involves reacting an amine-containing component with a thiol-containing component in comparable mole ratios to generate a conjugate bearing a substituted or unsubstituted 1-thio-isoindole structure. Inventors are Xuechen LI and Hey Pui CHEUNG. The application was filed on August 22, 2023.
Yuhan Corporation Patent for Glucosylceramide Synthase Inhibitors
USPTO published patent application US20260098038A1 by Yuhan Corporation for novel 2,3-dihydro-1H-indene and 2,3-dihydrobenzofuran derivatives as glucosylceramide synthase (GCS) inhibitors. The compounds are intended for treating lysosomal storage disorders including Gaucher disease and Fabry disease, as well as neurodegenerative conditions such as Parkinson's disease and Tay-Sachs disease.
6-Aryl Isoindolin-1-ones mGlu2 Modulators, Apr 09
6-Aryl Isoindolin-1-ones mGlu2 Modulators, Apr 09
Shionogi Monocyclic GLP-1 Receptor Agonist Patent Application
Shionogi & Co., Ltd. filed USPTO Patent Application US20260098031A1 for a monocyclic compound demonstrating GLP-1 receptor agonist activity, along with pharmaceutically acceptable salts. The compound, classified under CPC codes C07D 405/14 and A61K 31/4439, is intended for pharmaceutical use. The application, published April 9, 2026, claims priority to the September 2023 filing date.
Methods and Compounds for Restoring Mutant p53 Function
USPTO published patent application US20260098032A1 disclosing compounds that bind mutant p53 proteins and restore their wild-type DNA-binding and tumor-suppressor activity. The compounds are directed at reducing cancer progression in tumors harboring p53 mutations. The application was filed on 2025-05-15 under CPC classes C07D 405/14 and related organic chemistry subclasses.
Jacobio Pharmaceuticals Patent on Solid Forms of Compound I or Salts Thereof
USPTO published Jacobio Pharmaceuticals' patent application (US20260098039A1) for solid forms of Compound I, a potential cancer therapeutic compound, and its salts. The patent covers novel solid forms, preparation methods, pharmaceutical compositions, and therapeutic uses. The application was filed August 16, 2023, and published April 9, 2026.
Novel Crystalline Form of Enavogliflozin and Preparation Method
The USPTO published patent application US20260098033A1 for a novel crystalline form of enavogliflozin, an SGLT2 inhibitor for diabetes treatment. The new form exhibits improved thermodynamic stability, reduced hygroscopicity, enhanced long-term storage characteristics, and faster drug absorption compared to prior known forms. The application includes the preparation method and covers pharmaceutical compositions containing the crystalline form.
2H-Benzotriazole Derivative for Treating Premature Ejaculation
USPTO published patent application US20260098034A1 for a 2H-benzotriazole derivative compound and pharmaceutical composition for treating premature ejaculation. The novel benzisothiazole compound demonstrated superior anti-premature ejaculation activity compared to dapoxetine in in-vivo testing. Six inventors are listed with a filing date of August 23, 2023.
Salts and Solid Forms of Piperidine-2,6-Dione for Treating Disorders
USPTO published patent application US20260098035A1 on April 9, 2026, covering novel salts and solid forms of (S)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione. Inventors Lianfeng HUANG, Daozhong ZOU, and Tsz Chung LAI filed the application on September 19, 2023, claiming pharmaceutical compositions for treating, preventing, and managing various disorders.
Heteroaryl Pyridazine Carboxamides For Cancer Treatment
The USPTO published patent application US20260098036A1 filed by Deutsches Krebsforschungszentrum covering 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds for cancer treatment. The application claims novel chemical compounds, methods of preparation, pharmaceutical compositions, and methods of treating cancer and disorders associated with aberrant AHR signaling.
Multi-Fused Ring Compound for Diabetes, Obesity
USPTO published patent application US20260098037A1 for a multi-fused ring compound targeting diabetes and obesity. The application (filed September 22, 2025 by inventors Baomin Liu, Yan Zhu, Jinfa Hu, and Yu Huang) claims a compound of formula (I), its stereoisomers, and pharmaceutical compositions containing the compound for treating metabolic diseases. This is a routine patent publication providing public notice of the pending application and its claimed scope.
MHRA-NICE Aligned Pathway Accelerates Patient Access to Medicines by 3-6 Months
The MHRA and NICE launched an aligned pathway that synchronizes regulatory approval with health technology assessment, enabling new medicines to reach NHS patients 3-6 months earlier than previous timelines. This integration brings together the Medicines and Healthcare products Regulatory Agency and the National Institute for Health and Care Excellence to deliver simultaneous regulatory and reimbursement decisions.
P80 Protein Treatment Method Using Pharmaceutical Composition Comprising Neurotoxin Associated Polypeptide
The USPTO published patent application US20260098066A1 assigned to Prime Bio, Inc., covering a method of treating disorders using a pharmaceutical composition comprising a p80 neurotoxin associated polypeptide (NAP) derived from Clostridium Botulinum Type E. The p80 acts as a tight junction modulator to enhance intestinal epithelium permeability, facilitating drug delivery and increasing bioavailability of therapeutic agents including drugs, small molecules, proteins, and biomolecules.
Methods of Stimulating Appetite Using Non-Naturally Occurring Melanocortin Receptor Antagonist Analogs
The USPTO published patent application US20260098072A1 by inventor Russell Potterfield on April 9, 2026, covering methods of increasing body weight and stimulating appetite using non-naturally occurring melanocortin receptor antagonist analogs. The application, filed April 18, 2025, relates to pharmaceutical compositions administered via parenteral routes such as subcutaneous injection for subjects requiring appetite stimulation and weight gain.
GLP-1 Analog for Treatment of GLP-1 Related Diseases
USPTO published patent application US20260098071A1 for a novel human GLP-1 analog invented by Tao Sun. The disclosed analog demonstrates improved efficacy compared to natural GLP-1 sequence in treating obesity, type 2 diabetes mellitus, fatty liver, and mood disorders including anxiety and depression. The application was filed on December 4, 2024, under application number 18968327.
SMAGP Fusion Molecules Modulate Leukocyte Activity
USPTO published patent application US20260098070A1 disclosing fusion molecules comprising a SMAGP extracellular domain designed to modulate leukocyte activity. The application covers polynucleotides, vectors, and host cells encoding these molecules along with methods of making and using them. Inventors include Loise M. Francisco-Anderson, Sandeep Kumar, Sarah Elizabeth Carden, Christophe Quéva, and Nenad Grmusa, with filing date July 7, 2025.
Recombinant Lubricin Patent - Schmidt and Jay Inventors
USPTO published patent application US20260098069A1 for recombinant isoforms of human-like lubricin (PRG4 glycoprotein) invented by Tannin A. Schmidt and Gregory D. Jay. The patent covers new lubricin isoforms with novel glycosylation patterns and methods for commercial-scale manufacturing using recombinant production methods.
DWORF Peptide SERCA Pump Activator Heart Failure Treatment
The USPTO published patent application US20260098067A1 by researchers at the University of Texas System covering the DWORF (Dwarf Open Reading Frame) peptide, a native SERCA pump activator for treating heart failure and disorders characterized by cytosolic calcium overload. The application claims compositions and methods using this positively inotropic and lusitropic therapeutic agent.
GC-Globulin Patent Claims Diabetes Treatment
USPTO published patent application US20260098068A1 for GC-globulin or variants for treating diabetes, filed September 22, 2023. The application names David Hodson, Katrina Viloria, and Martin Hewison as inventors and covers compositions and methods for diabetes treatment using the vitamin D-binding protein.
Pharmaceutically Acceptable Salt and Crystal Form of Tetrahydronaphthalene Derivative
USPTO published patent application US20260098027A1 for a pharmaceutically acceptable salt and crystal form of a tetrahydronaphthalene derivative, specifically covering (S)-3-(5-(4-((1-(4-((1R,2R)-6-hydroxy-2-isobutyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and its preparation method. Inventors include Lina Jia, Junran Yang, Zhenxing Du, Lin Wang, Qiyun Shao, and Jun Feng.
MITSUI CHEMICALS Carbamate Compound Patent Application
MITSUI CHEMICALS, INC. published a patent application (US20260098022A1) for a carbamate compound with specific molecular structure parameters. The application describes compounds where R1-R4 form monocyclic or polycyclic rings through various substituent linkages. CPC classifications include C07D 295/205, C07C 271/44, and C07C 275/32. Competitors developing similar chemical structures should review claims upon grant.
Rhodium Catalyst Method for Hydrogenation of Furfural to Bio-Fuel
The USPTO published patent application US20260098023A1 by King Fahd University of Petroleum and Minerals, covering a method for hydrogenating furfural to furfuryl ethyl ether bio-fuel using a rhodium nanoparticle catalyst (0.9-1.1 wt.% on alumina). The reaction achieves at least 99% conversion and 99% selectivity under ethanol and hydrogen atmosphere.
PARP1 Inhibitors and Uses Thereof
USPTO published patent application US20260098024A1 disclosing PARP1 inhibitor compounds and pharmaceutical compositions for cancer treatment. The application, filed on January 26, 2023 under application number 18833362, names six inventors including Robert L. Hoffman and Stephen W. Kaldor and covers compounds classified under C07D 401/12 and C07D 471/04.
Dimeric GYS1 Inhibitor Compounds for Metabolic Disorder Treatment
USPTO published patent application US20260098025A1 covering dimeric compounds of formula (I) as inhibitors of glycogen synthase 1 (GYS1), along with methods of preparing the compounds and methods of treating GYS1-mediated diseases, disorders, or conditions. The application names nine inventors including David John Morgans Jr. and Christopher Joseph Sinz, with an original filing date of September 13, 2023.
M4 Receptor Activators Treat Alzheimer's Parkinson's Schizophrenia
The USPTO published patent application US20260098026A1 for M4 receptor activator/modulator compounds of Formula I, filed September 15, 2023. The compounds are intended for treating M4-mediated neurological disorders including Alzheimer's Disease, Parkinson's Disease, schizophrenia, pain, addiction, and sleep disorders. The application covers the compounds, N-oxides, salts, preparation processes, intermediates, and pharmaceutical compositions.
Amgen KIF18A Kinase Inhibitor Patent Application for Cancer Treatment
USPTO published Amgen's patent application US20260098029A1 for KIF18A protein-modulating compounds intended to treat cancer and cancer-related diseases. The application discloses compounds of formula (I) with synthetic intermediates, pharmaceutical compositions, and methods of treatment. The 15 named inventors include researchers from Amgen's medicinal chemistry and oncology teams.
Bristol-Myers Squibb Hemoglobinopathy Treatment Compounds
USPTO published patent application US20260098028A1 by Bristol-Myers Squibb Company covering compounds for treatment of hemoglobinopathies. The application includes claims for pharmaceutical compositions and methods of preventing or treating these blood disorders. The A1 publication followed a September 2025 filing date with European application number 19328416.
Particulate Active Premix Antiperspirant Aluminum Chloride Apr 09
Particulate Active Premix Antiperspirant Aluminum Chloride Apr 09
UV Absorbing System With Physical Material Coloring Agent
USPTO published L'OREAL's patent application (US20260096967A1) for UV-absorbing compositions containing physical UV-attenuating materials and coloring agents. The application covers methods of making and using such cosmetic compositions for sun protection. The application was filed October 3, 2025.
Active Premix Aluminum Zirconium Salts Antiperspirant
USPTO published patent application US20260096968A1 by Wade Charles Henke, Shawn David McConaughy, and David Frederick Swaile covering a particulate active premix composition containing an aluminum zirconium salt, an amino acid, and greater than 1% of an alkali metal salt for use in antiperspirant products.
Active Premix for Antiperspirant Products Patent Application
The USPTO published patent application US20260096962A1 covering a particulate active premix composition for antiperspirant products. The composition combines basic aluminum chloride of formula Al2(OH)3.778Cl2.222 to Al2(OH)5.048Cl0.952, an amino acid, an alkaline earth metal salt, and greater than 1% of an alkali metal salt and/or magnesium chloride. Inventors: Wade Charles Henke, Shawn David McConaughy, and David Frederick Swain.
L'OREAL UV Absorbing System with Oil for Preventing Material Aggregation
The USPTO published L'OREAL's patent application (US20260096963A1) for a UV absorbing composition combining physical UV-attenuating materials with oils to inhibit particle aggregation. The invention targets improved stability in sunscreen and cosmetic formulations. The application was filed on October 4, 2024, under application number 18906290.
UV-Absorbing Emulsion with Physical UV-Attenuating Material, Surfactant, and Thickener
USPTO published L'OREAL's patent application (US20260096964A1) for UV-absorbing emulsion compositions containing physical UV-attenuating material, surfactant, and thickening agents. The application was filed on October 4, 2024, under Application No. 18906424. Inventors include Anil Shah, David Enoch Gee II, Brian Bodnar, and Margaret Kindschuh. This patent publication affects cosmetics and personal care product manufacturers developing UV-protective formulations. Companies should review the claims to assess potential overlap with their own product development pipelines and IP strategies.
L'OREAL UV Emulsion Patent with Physical UV-Absorbing System
USPTO published L'OREAL's patent application US20260096965A1 for emulsion compositions containing a UV-absorbing system with physical UV-attenuating material and spherical plus amorphous particulate materials. The patent covers methods of making and using such compositions for UV protection. The application was filed October 4, 2024.
L'OREAL UV Absorbing Composition with Physical Filters and Three Emollients
USPTO published L'OREAL's patent application (US20260096966A1) for a UV-absorbing composition combining at least one physical UV-attenuating material with an emollient system containing at least three emollients. The invention includes methods of making and using such compositions for topical applications. The application was filed on October 3, 2025, under Application No. 19349244.
Targeted Amatoxin Conjugate for Treatment of Solid Tumors
Heidelberg Pharma Research GmbH has published a US patent application (US20260097093A1) for a targeted amatoxin-linker conjugate designed to treat solid tumors. The application discloses an amatoxin-linker construct where R1 and R2 are each OH, R3 is NH2 or a linker, R4 is H or a linker, and R5 is absent or O, with the conjugate useful in manufacturing binding moiety-toxin therapeutics. Filing date was October 6, 2025.
Pharmaceutical Composition Containing Mitochondria-Targeting Compound for Treating Macular Degeneration
The USPTO published patent application US20260097092A1 filed by Ulsan National Institute of Science and Technology for a pharmaceutical composition containing mitochondria-targeting compounds as active ingredients for treating macular degeneration and other retinal diseases. The application specifically covers compounds that induce apoptosis of senescent cells for prevention and treatment of aging-related diseases. The application was originally filed on January 11, 2023.
Glutathione Trisulfide Patent for Chemotherapy-Induced Neuropathy
Glutathione Trisulfide Patent for Chemotherapy-Induced Neuropathy
Pegylated Lipoprotein Nanoparticles Treat Neurodegenerative Diseases
The USPTO published patent application US20260097095A1 for pegylated reconstituted high-density lipoprotein nanoparticles designed to prevent or treat neurodegenerative diseases. The application, filed by inventors Lee, Kim, and Kim on October 10, 2025, was published on April 9, 2026.
4-1BBL AND IL-12 COMBINATION THERAPY FOR GLIOBLASTOMA
The USPTO published patent application US20260097096A1, a new intellectual property grant covering methods of treating glioblastoma using 4-1BBL administered via adeno-associated virus (AAV-F) in combination with recombinant IL-12 delivered by intratumoral injection. The patent names Koen Breyne, Xandra O. Breakefield, and Thorsten R. Mempel as inventors. Biotech and pharmaceutical companies developing cancer immunotherapies must monitor this IP landscape.
Painless NGF Compositions for Fracture Repair
The USPTO published patent application US20260097099A1 for painless nerve growth factor (NGF) compositions for bone fracture repair, filed by inventors Chelsea Bahney, Tejal Desai, Kevin Rivera, and Chengbiao Wu. The application covers pharmaceutical compositions comprising biomaterial carriers with painless NGF for stimulating bone fracture healing. Filing date was April 23, 2025.
DBI Protein Modulation Methods for Autophagy and Metabolic Regulation
The USPTO published patent application US20260097094A1 disclosing methods for modulating diazepam binding inhibitor (DBI) protein activity to regulate autophagy and metabolic processes. The inventors demonstrate that DBI neutralization via monoclonal antibodies or active immunization induces autophagy, enhances starvation-induced weight loss, reduces food intake upon refeeding, and reduces weight gain from hypercaloric diets. The patent covers pharmaceutical compositions and therapeutic applications for metabolic disorders.
Novel Aromatic Ring Derivative Containing Amide Substitution as TYK2 Inhibitor
The USPTO has published patent application US20260098017A1 for a novel aromatic ring derivative containing amide substitution as a TYK2 inhibitor for treating inflammatory and autoimmune diseases including psoriasis, psoriatic arthritis, dermatitis, lupus, inflammatory bowel disease, and rheumatoid arthritis. The application was filed December 22, 2023, with inventors including Wenzhi Wang, Shuangyong Sun, and colleagues. The invention demonstrates therapeutic efficacy in psoriasis and asthma animal models with good druggability, stability, and safety profiles.
NSAID Conjugate Anti-Inflammatory Compounds Via Microwave Synthesis
The USPTO published patent application US20260098019A1 for microwave-synthesized NSAID conjugate compounds containing triazolyl heterocycles. The compounds are derivatives of FDA-approved anti-inflammatory drugs such as ibuprofen and indomethacin. The application claims improved anti-inflammatory efficacy with reduced ulcerogenic effects and selective COX-2 inhibition over COX-1.
Bicyclic 1,4-Diazepanones and Therapeutic Uses
The USPTO published patent application US20260098018A1 disclosing bicyclic 1,4-diazepanone compounds of formula (I) and their therapeutic uses for treating diseases responsive to modulation of skeletal sarcomere contractility. The application names 15 inventors and was filed July 7, 2025 under Application No. 19261878.
Method and System for Fully Continuous-Flow Preparation of Nitroimidazole Antimicrobial Agent
USPTO published patent application US20260098016A1 for a fully continuous-flow method of synthesizing nitroimidazole antimicrobial agents. The method uses glyoxal aqueous solution, acetaldehyde aqueous solution, and ammonium hydroxide as raw materials through multi-step chemical reactions. Inventors include Fener Chen, Minjie Liu, Li Wan, Yajiao Zhang, Xingpeng Cai, and Zhisheng Yang. The system includes micromixers, microreactors, back pressure valves, gas-liquid separators, and online solvent switching units.
Crystalline Imidazole Polymorphs for Mitochondria and Cardiovascular Treatment
USPTO published patent application US20260098015A1 for crystalline polymorphic forms of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole. The compound is directed to treating mitochondria-related disorders and cardiovascular disorders or conditions. The application was filed May 19, 2025 and names Muralikrishna DUVVURI, Donald Herbert LAMUNYON, and Micah Jeffrey BODNER as inventors.
Ionizable Lipidoid Compositions and Therapeutic Uses Thereof
Ionizable Lipidoid Compounds for Therapeutic Agent Delivery
Dextrorphan Amino Acid Ester Stereoisomer Conjugates with Improved Bioavailability
The USPTO published patent application US20260098013A1 disclosing amino acid ester conjugates of dextrorphan using diastereomerically pure amino acids to improve bioavailability. Inventors include Sven Guenther, Travis Mickle, Sanjib Bera, and Amarraj Chakraborty. The application covers pharmaceutical compositions and methods of treating diseases using these conjugates.
Tetrahydroacridinone Analogues for Malaria Treatment and Prevention
The USPTO published patent application US20260098012A1 for tetrahydroacridinone scaffold molecules exhibiting antimalarial activity against multiple Plasmodium spp. strains in erythrocytic and exoerythrocytic stages. The application, filed December 11, 2025, names 11 inventors including Dennis E. Kyle and Steven Maher and covers pharmaceutical compositions for malaria treatment and prevention.
Deuterated Organic Compounds for Schizophrenia and Depression Treatment
The USPTO published patent application US20260098011A1 covering deuterated organic compounds of Formula I and II for modulating dopamine and serotonin neurotransmission. The compounds are directed toward treating disorders including schizophrenia and depression. The application was filed on June 11, 2025, under application number 19235237.
Ultra-Long-Acting Platform Comprising Fc-Advanced Fatty Acid Chain Extending Drug Half-Life
The USPTO published patent application US20260097125A1 for an ultra-long-acting drug delivery platform combining immunoglobulin Fc with a modified C14-24 fatty acid chain. The conjugated molecule structure 'active molecule-Fc-Cn' is designed to extend the half-life of therapeutic active molecules. The application was filed on September 22, 2023, with eight inventors including Faming Zhang, Yimin Hu, and colleagues.
Blaine Labs Recalls Revitaderm and Tridergel Wound Care Gel Due to Microbial Contamination
Blaine Labs, Inc. has voluntarily recalled three lot numbers of Revitaderm and Tridergel Wound Care Gel products (BL3608, BL3435, BL3525) distributed nationwide to healthcare providers due to contamination with Lysinibacillus fusiformis, an environmental spore-forming bacterium. The contaminated 1 oz. and 3 oz. antiseptic wound gels pose infection risk to patients with open wounds, compromised skin barriers, or weakened immune systems.
Universal Peptide/MHC Complexes with Engineered Disulfide
The USPTO published patent application US20260097105A1 by Nikolaos SGOURAKIS for synthetic major histocompatibility complex (MHC) molecules featuring engineered disulfide linkages connecting heavy and light chains. The invention covers systems, formulations, and methods for generating universal peptide/MHC complexes using structure-guided modeling and design. Application No. 19114130 was filed September 28, 2023, with CPC classifications including A61K 39/001188, A61K 39/385, C07K 14/4748, and C07K 14/70539.
Flavivirus Vaccine Polynucleotides Inducing Protective CD8+ T Cell Immunity
USPTO published patent application US20260097108A1 by inventors Charneau et al. disclosing recombinant polynucleotides encoding non-structural antigens from Dengue virus (DENV), Zika virus (ZIKV), and Yellow Fever virus (YFV) designed to elicit protective CD8+ T-cell immune responses. The application covers polyepitope fusion polypeptides and lentiviral vectors for flavivirus vaccine development.
Recombinant Fusion Polypeptides Enable Bacteroides Cargo Secretion
Recombinant Fusion Polypeptides Enable Bacteroides Cargo Secretion
Erythroid Lineages from Pluripotent Cells
USPTO published patent application US20260097074A1 by Dhvanit Shah disclosing methods for generating hematopoietic lineages including erythroid progenitor cells, progenitor erythroblasts, and erythroid cells from human induced pluripotent stem cells (iPSCs) for cell therapy applications. The application covers efficient ex vivo processes for developing these lineages and isolated cell compositions produced by the methods.
Method to Change Tumor Associated Macrophage Polarization Using Magnetosomes and Radiation
USPTO published patent application US20260097075A1 by Université Paris Cité for a method to change tumor-associated macrophage polarization by exposing macrophages to magnetosomes and radiation. The invention aims to shift macrophages from M0 or Mi polarization to Mj polarization for potential cancer immunotherapy applications.
Removing Endogenous TCR Chains for Enhanced TCR-Based Immunotherapies
USPTO published patent application US20260097079A1 by Khosravi Maharlooei et al. disclosing methods for treating diseases using adoptive cell therapy with modified lymphocytes having inactivated endogenous TCRα and TCRβ chains. The application covers compositions and methods for enhanced TCR-based immunotherapies.
Cell Behavior Control Methods Without Genetic Modification
USPTO published patent application US20260097078A1 by inventors Victor TETS and Georgy TETS covering products and methods for managing cell behavior, cell memory, and erasure of cell memory without genetic modification. The application relates to therapeutic, diagnostic, agricultural, and biomanufacturing applications. The invention distinguishes itself from prior art by enabling control of cellular properties without mutagens, gene introduction, or environmental condition changes.
Modified Gamma Delta T Cells for Cancer Therapy
USPTO published patent application US20260097077A1 for a method of treating cancer using gamma delta T cells modified with XBP1 gene or protein inhibitors. The modified T cells demonstrate enhanced antitumor activity in tumor microenvironments with endoplasmic reticulum stress. Inventors are Minkyung Song, Hocheol Shin, and Ji Yun Park, with application filed September 4, 2025.
Exosomes from Mesenchymal Stem Cells for Alzheimer's Treatment
USPTO published patent application US20260097080A1 covering exosomes isolated from mesenchymal stem cells for reducing inflammation and treating Alzheimer's disease. The application claims exosomes exposed to conditioned media with microglial cells in the presence of LPS or beta-amyloid oligomer. This is a publication of a pending application, not a granted patent.
Ammonium Chloride Formulations for Viral Defense
The USPTO published patent application US20260097072A1 for ammonium chloride formulations designed to support human natural defense against viral infections. The invention claims compositions and methods using lysosomotropic agents, such as ammonium chloride (NH4Cl), to prevent viral uncoating within lysosomes of infected cells. The patent names Nikolaos Tsirikos-Karapanos and Nikolaos Drakoulis as inventors.
Pharmaceutical Composition Containing Neonatal Pig-Derived Mesenchymal Stem Cells for Treating Non-Porcine Animals
USPTO published patent application US20260097081A1 by Fukuoka University for a pharmaceutical composition containing neonatal pig-derived mesenchymal stem cells. The cells produce at least one humoral factor selected from TGF-β1, TGF-β2, VEGF-A, and VEGF-C for therapeutic use in treating cardiovascular conditions, wounds, and decubitus in non-porcine animals. The application was filed on October 10, 2025.
Cbfβ-Expressing Vascular Smooth Muscle Cells for Age-Related Disease Treatment
The USPTO published patent application US20260097084A1 by Kyungpook National University Industry-Academic Cooperation Foundation covering a pharmaceutical composition containing Cbfβ-expressing vascular smooth muscle cells or culture fluid for preventing or treating age-related diseases. The invention demonstrates that Cbfβ expression in vascular smooth muscle cells inhibits osteoclast differentiation and prevents vascular calcification, offering potential therapeutic applications for conditions such as osteoporosis and age-related vascular disorders.
Heterotrophic Skin Bacteria Composition for Treating UV Damage and PLE
The USPTO published patent application US20260097086A1 by inventor Catherine O'Neill for a composition comprising heterotrophic skin bacteria or bacterial extract for modulating cytokine expression in skin cells. The composition is intended for preventing and treating skin damage caused by UV light and for treating polymorphous light eruption (PLE).
Human Hair Follicle-Derived Conditioned Media and Method of Making Same
USPTO published patent application US20260097082A1 covering methods for preparing hair follicle-derived conditioned media containing bioactive factors. The hair follicles are retrieved non-invasively and cultured to secrete therapeutic compounds. The application covers compositions for therapeutic and cosmetic treatments including hair restoration and skin repair.
PTGS2 Skin Disorders Carnosine Compound Treatment Method
USPTO published patent application US20260096978A1 disclosing a method for preventing, mitigating, or treating PTGS2-induced skin disorders using carnosine compounds of formula (I) applied to human skin. The application, filed November 14, 2022, names five inventors and covers cosmetic and dermatological formulations.
Engineered Immune Cells CAR-T CAR-NK BCMA TACI Cancer Therapy Patent Application
USPTO published patent application US20260097076A1 for engineered immune cells (T cells and NK cells) expressing chimeric antigen receptors targeting BCMA and/or TACI antigens for cancer therapy. The application discloses armored CAR-T and CAR-NK cells with enhanced features for tumor treatment. Filed September 20, 2023, by inventors Chen, Agrahari, Zhao, Nguyen, Zhang, Jiang, and O'Callaghan.
Liposome Composition Comprising Sphingomonas Olei Culture Extract for Skin Delivery
USPTO published patent application US20260096958A1 by six inventors including Won Woo Choi and Byong Jun Choi for a liposome composition encapsulating Sphingomonas olei culture extract for enhanced skin regeneration and transdermal absorption. The application covers cosmetic compositions for topical skin delivery applications, classified under CPC codes A61K 8/14 and A61Q 19/00.
Aerosol Antiperspirant Composition with Basic Aluminum Chloride Salt Formula
USPTO published patent application US20260096955A1 for an aerosol antiperspirant composition containing a basic aluminum chloride salt (formula Al2(OH)3.778Cl2.222 to Al2(OH)5.048Cl0.952), an amino acid, an alkaline earth metal salt, and greater than 1% of an alkali metal salt and/or magnesium chloride. The concentrate includes a particulate active premix, carrier, and fragrance. The application names five inventors and was filed October 3, 2025.
LIHEAP Household Data Collection Report Reinstatement Request
HHS Administration for Children and Families proposes to reinstate the LIHEAP Household Report (OMB #0970-0060) with proposed changes to reduce reporting burden. States, DC, and Puerto Rico would submit household statistics by assistance type and funding source, while tribal grantees would submit simplified household counts. Comments are due June 8, 2026.
Procedures for Requests From Tribal Lead Agencies To Use CCDF Funds for Construction or Major Renovation
The Office of Child Care (OCC) under HHS proposes to extend and modify an existing information collection for Tribal Lead Agencies requesting Child Care and Development Fund (CCDF) funds for child care facility construction or renovation. The updated Program Instruction significantly streamlines requirements, reducing burden by 70% from 20 hours to 6 hours per response, cutting 19 pages and eliminating 5 requirements while maintaining statutory compliance under 42 U.S.C. 9858m(c)(6). Comments are due May 11, 2026.
Annual Survey of Refugees Information Collection Extension Request
The Administration for Children and Families (ACF) seeks OMB approval to extend the Annual Survey of Refugees (ASR) through 2027, maintaining the existing survey form for the 2025 and 2026 collection cycles. The ASR collects data from approximately 6,400 refugee households that entered the U.S. within the previous 5 fiscal years, supporting the Office of Refugee Resettlement's congressional reporting requirements under the Refugee Act of 1980.
DNV Healthcare Hospital Accreditation Program Continued Approval Application
CMS published notice of DNV Healthcare USA Inc.'s application for continued recognition as a national accrediting organization for its hospital accreditation program under Medicare and Medicaid. The agency seeks public comment on whether DNV meets CMS standards for continued approval. Comments must be submitted by May 11, 2026.
National Eye Institute Board of Scientific Counselors Closed Meeting Notice
The NIH National Eye Institute published a closed meeting notice for the Board of Scientific Counselors on April 27, 2026. The meeting will review and evaluate personnel qualifications and performance, and the competence of individual investigators. The meeting is closed pursuant to FACA exemptions for personal privacy.
Center for Scientific Review Notice of Closed Meetings
The NIH Center for Scientific Review published a notice announcing five closed meetings scheduled for May 5-6, 2026, to review grant applications across topics including aging/neurological/behavioral health, cardiovascular clinical trials, cancer genetics, gene regulation, and pathogenic eukaryotes. All meetings will be held virtually and closed to the public pursuant to the Federal Advisory Committee Act.
HRSA Extends Small Health Care Provider Quality and Delta States Network Programs
HRSA has issued a notice extending two grant programs for rural healthcare providers. The Small Health Care Provider Quality Improvement Program receives a 1-year extension for 21 award recipients (HRSA-22-093 cohort), while the Delta States Network Development Program extends 12 award recipients (HRSA-23-031 cohort). Total funding amounts to $15,928,583 for the period August 1, 2026, through July 31, 2027.
Projected Reality variance application, FDA, California, Apr 8
Projected Reality variance application, FDA, California, Apr 8
ACE Surgical sutures recall due to unlicensed medical devices
Health Canada issued a Type II recall for ACE Surgical Supply® PGA Absorbable Sutures and Absorbable Gut Sutures distributed in Canada. BioHorizons Canada is conducting the recall because manufacturer ACE Surgical Supply Co. Inc. voluntarily ceased operations and discontinued its medical device licenses in Canada, resulting in unlicensed devices on the market. All lots of 17 affected catalogue numbers are subject to this recall. Healthcare providers who have distributed these sutures must cease use and contact the importer.
Nucletron B.V. Intrauterine Tube Recall - Tip Detachment
Health Canada issued a Type II medical device recall for Nucletron B.V. Intrauterine Tubes (catalog numbers 152019-00 through 126015-01) affecting 44 product lots. The recall addresses a safety concern where the tip of the 4mm diameter IU tube detached and remained within a patient during use. Healthcare providers should contact the manufacturer for additional information.